|
|
|
| Secure, sustainable raw material supply is at the core of every biopharmaceutical innovation. Breakthrough therapies leveraging cell culture media depends on quality products, and companies rely on strong supplier relationships to compete in the industry. Nu-Tek BioSciences meets your supply and sustainability needs with our state-of-the-art facility and 100% animal-free products. Improve your cell culture titer and simplify your supply without compromising on quality and environmental impact. Contact us today. |
|
|
|
|
By GlobalData | Each month, Outsourced Pharma works in conjunction with PharmSource, part of GlobalData, to present its “Contract Manufacturing: Opportunities and Threats (CMOT) Report” to our readers. The report identifies CDMOs that might be impacted by key events affecting their clients, including company acquisitions, product acquisitions and licenses, product approvals, late clinical product terminations, and FDA rejections. | |
|
|
| Precision Polymorph Screening With Electron Diffraction | Application Note | Ardena | See how polymorph screening with electron diffraction uncovers hidden forms, enabling precise identification and reliable quantification of minor phases affecting performance and manufacturability. |
|
|
| Developing Robust mRNA Processes In A cGMP Environment | Poster | By Clemens Jakobi, Michal Domański, and Telmo Graça, Lonza | Explore current and emerging technologies to optimize mRNA manufacturing, especially when considering commercial production and the validation of processes in a cGMP environment. |
|
|
| Winning With Analytical Strategy | Article | LOTTE Biologics | An integrated analytical strategy connects process parameters, critical quality attributes, and manufacturing performance to support informed decisions across biologics development. |
|
|
| Getting Bispecific Antibody Release Testing Right | Article | By Dr. Fabio Rossi, Dr. Camila Ortega, and Dr. Erika Kovacs, Abzena | Gain insight into how stable linkers and controlled payload loading reduce clearance risks and support scalable antibody-nucleic acid therapies. |
|
|
|
| Safeguarding Biologic Quality And Performance | Article | Coriolis Pharma | A science‑driven roadmap, from QTPP to QbD and phase‑appropriate strategies, helps ensure biologics stability, manufacturability, and a smooth path to successful commercialization |
|
|
| Device Design For Usability And Risk Reduction | Article | Dr. Sylvine Raverdy-Wilson, BD Medical - Pharmaceutical Systems | Growing use of large‑volume subcutaneous therapies is increasing demand for wearable injectors that reduce user error, simplify preparation, and enhance safety through human‑factors‑focused design. |
|
|
|
|
|
|
|
|
|
| Connect With Bioprocess Online: |
|
|
|
